VEGFR
Les inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (VEGFR) sont des composés qui bloquent la signalisation du VEGFR, un récepteur clé dans la voie VEGF, cruciale pour l'angiogenèse. Les inhibiteurs de VEGFR empêchent la formation de nouveaux vaisseaux sanguins qui fournissent des nutriments et de l'oxygène aux tumeurs, inhibant ainsi la croissance tumorale. Ces inhibiteurs sont largement utilisés en thérapie et en recherche contre le cancer pour étudier les mécanismes de l'angiogenèse et développer des traitements anticancéreux. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de VEGFR de haute qualité pour soutenir vos recherches en oncologie, biologie vasculaire et angiogenèse.
244 produits trouvés pour "VEGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
T-1-MCPAB
T-1-MCPAB, a VEGFR-2 inhibitor with an IC50 of 0.135 µM, effectively suppresses MCF7 cell migration and has applications in cancer research [1].Degré de pureté :98%Couleur et forme :Odour SolidTyrosine Kinase Inhibitor Library
A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase relatedCouleur et forme :Odour SolidRef: TM-L2200
1mgÀ demander30μL*10mM (DMSO)À demander50μL*10mM (DMSO)À demander100μL*10mM (DMSO)À demander250μL*10mM (DMSO)À demanderKinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Couleur et forme :Odour SolidRef: TM-L1600
1mgÀ demander30μL*10mM (DMSO)À demander50μL*10mM (DMSO)À demander100μL*10mM (DMSO)À demander250μL*10mM (DMSO)À demanderAngiogenesis related Compound Library
A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and highCouleur et forme :Odour SolidRef: TM-L4800
1mgÀ demander30μL*10mM (DMSO)À demander50μL*10mM (DMSO)À demander100μL*10mM (DMSO)À demander250μL*10mM (DMSO)À demander5Z-7-Oxozeaenol
CAS :5Z-7-Oxozeaenol: TGF-β-activated kinase 1 inhibitor, IC50 8.1 nM; VEGF-R2 inhibitor, IC50 52 nM; weak MEK1 inhibitor, IC50 411 nM.Formule :C19H22O7Degré de pureté :99%Couleur et forme :SolidMasse moléculaire :362.37VEGFR-2-IN-59
VEGFR-2-IN-59 (Compound 3h) is an inhibitor of VEGFR2 with an IC50 of 3.73 µM. It exhibits cytotoxicity in cancer cell lines A549, HT-29, A375, MCF7, and NHDF, with IC50 values of 20.91, 19.70, 9.63, 17.43, and 20.71 μM, respectively. VEGFR-2-IN-59 also inhibits tubular structure formation and demonstrates anti-angiogenic properties.Formule :C19H20N6O4Couleur et forme :SolidMasse moléculaire :396.4FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Couleur et forme :LiquidVEGF-IN-1
VEGF-IN-1 (compound 6) reduces the release of VEGF in U87-MG cells and inhibits angiogenesis in vitro. Additionally, it suppresses cell proliferation by inducing autophagy in tumor cells, with an IC50 value of 28.35 μM against U87-MG cells.Formule :C27H22Cl2N4RuCouleur et forme :SolidMasse moléculaire :574.47VEGFR-2-IN-29
CAS :VEGFR-2-IN-29 is a VEGFR2 inhibitor.Formule :C16H11N3O3Degré de pureté :99.59%Couleur et forme :SolidMasse moléculaire :293.28VEGFR-2-IN-31
VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase andFormule :C15H10F2N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :300.26Vulinacimab
CAS :Vulinacimab (HLX-06) is a mAb targeting VEGFR-2, used in cancer research, vital for tumor angiogenesis and endothelial cell functions.Couleur et forme :LiquidAbicipar pegol
CAS :Abicipar pegol is an anti-VEGF DARPin for ocular diseases, reducing retinal thickness and leakage.Couleur et forme :LiquidSozinibercept
CAS :Sozinibercept (OPT 302; VGX-300), a VEGFR-3 inhibitor, blocks VEGF-C/D to curb angiogenesis and vascular leakage, and treats rat diabetic retinal edema.Couleur et forme :LiquidTovecimig
Tovecimig is a G1-scFvlh_L-κ type bispecific antibody targeting VEGFA/DLL4.Couleur et forme :Odour LiquidOlinvacimab
CAS :Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis.Degré de pureté :97.7% (SDS-PAGE); 97.9% (SEC-HPLC) - 97.7% (SDS-PAGE); 97.9% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :148.16 kDaElpamotide
CAS :Elpamotide is a vaccine consisting of a VEGFR2-169 peptide.Formule :C47H76N16O13Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1073.21GNQWFI
CAS :GNQWFI, an anti-Flt1 peptide, functions as a VEGFR1-specific antagonist. It inhibits interactions between VEGFR1 and various ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF), and suppresses VEGF-induced endothelial cell migration and tubulogenesis. GNQWFI holds potential for research in cancer, asthma, and other ocular diseases.Formule :C37H49N9O9Couleur et forme :SolidMasse moléculaire :763.84Conbercept
CAS :Conbercept (KH902) is a fusion protein comprising the second immunoglobulin C-like domain of FLT1 and the third and fourth immunoglobulin C-like domains of KDRDegré de pureté :98%Couleur et forme :LiquidRanibizumab
CAS :Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121,Degré de pureté :98%Couleur et forme :LiquidMasse moléculaire :149.19KDPulocimab
CAS :Pulocimab, an anti-VEGFR2 monoclonal antibody (mAb), is utilized in cancer research [1].Couleur et forme :Liquid
